Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
Saved in:
| Title: | Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. |
|---|---|
| Authors: | Cao J; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Zhu Z; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Wang H; Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA., Nichols TC; Drug Safety Research and Development, Pfizer Inc., San Diego, CA, 92121, USA., Lui GYL; Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA., Deng S; Biostatistics, La Jolla Laboratories, Pfizer Inc., San Diego, CA, 92121, USA., Rejto PA; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., VanArsdale T; Tumor Cell Biology, Oncology Research and Development, Pfizer Inc., San Diego, CA, 92121, USA., Hardwick JS; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Weinrich SL; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Wei P; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA. ping.wei@pfizer.com. |
| Source: | Oncogene [Oncogene] 2019 May; Vol. 38 (21), pp. 4125-4141. Date of Electronic Publication: 2019 Jan 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
